For the Inventor, By the Inventor

Enter assignee name

Evanston, IL, United States of America

Aptinyx Inc.

USPTO Granted Patents = 28

% Expired Patents = 3.6

EPO Patents = 8

Trademarks = 1

Forward Citations = 364

Loading Chart...

Loading Chart...

2 inventors (with patents filed for the assignee):

M Amin Khan (28 out of 46 patents)

John Adams Lowe, Iii (13 out of 83 patents)

John A Iii Lowe (0 patent)

4. Amin M Khan (0 patent)

5. John A Iii Lowe (0 patent)

28 patents: Sort by Forward Citations

1. 11578072 - Spiro-lactam NMDA receptor modulators and uses thereof (2023-02-14),

2. 11530223 - Spiro-lactam NMDA receptor modulators and uses thereof (2022-12-20),

3. 11512051 - Spiro-lactam NMDA receptor modulators and uses thereof (2022-11-29),

4. 11427585 - Spiro-lactam NMDA modulators and methods of using same (2022-08-30),

5. 11376250 - Spiro-lactam NMDA receptor modulators and uses thereof (2022-07-05),

6. 11370790 - Spiro-lactam NMDA modulators and methods of using same (2022-06-28),

7. 11299495 - Spiro-lactam NMDA receptor modulators and uses thereof (2022-04-12),

8. 11077094 - Spiro-lactam NMDA receptor modulators and uses thereof (2021-08-03),

9. 11028095 - Spiro-lactam and bis-spiro-lactam NMDA receptor modulators and uses thereof (2021-06-08),

10. 10961189 - Spiro-lactam NMDA receptor modulators and uses thereof (2021-03-30),

11. 10918637 - Spiro-lactam NMDA receptor modulators and uses thereof (2021-02-16),

12. 10441572 - Spiro-lactam NMDA receptor modulators and uses thereof (2019-10-15),

13. 10441571 - Spiro-lactam NMDA receptor modulators and uses thereof (2019-10-15),

14. 10316041 - Spiro-lactam NMDA receptor modulators and uses thereof (2019-06-11),

15. 10273239 - Spiro-lactam NMDA receptor modulators and uses thereof (2019-04-30),

Aptinyx Inc. is a biopharmaceutical company dedicated to the discovery and development of innovative therapies for challenging neurologic disorders. They aim to transform the lives of patients suffering from conditions such as post-traumatic stress disorder (PTSD), Parkinson's disease, and traumatic brain injury (TBI). By leveraging their deep expertise in the field of NMDA receptor modulation, Aptinyx is advancing a robust pipeline of candidates that have the potential to address unmet medical needs and provide improved outcomes for patients.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Sep 22 2026

28 Patents

#11 in Evanston, IL

#640 in Illinois

#11,988 in US

#23,221 in the World

Evanston, IL, United States of America

Aptinyx Inc.

Forward Citations = 364

2 inventors:

M Amin Khan (28 out of 46 patents)

John Adams Lowe, Iii (13 out of 83 patents)

John A Iii Lowe (0 patent)

4. Amin M Khan (0 patent)

5. John A Iii Lowe (0 patent)

Please report any incorrect information to [email protected]

Loading…